PHARMACOKINETICS OF PROSTAGLANDIN E1 AND ITS MAIN METABOLITES AFTER INTRACAVERNOUS INJECTION AND SHORT-TERM INFUSION OF PROSTAGLANDIN E1 IN PATIENTS WITH ERECTILE DYSFUNCTION

Add time:07/31/2019    Source:sciencedirect.com

ABSTRACTPurposeAlprostadil (prostaglandin E1) is the preferred monotherapy for intracavernous injection in the diagnosis and treatment of erectile dysfunction. Our study was designed to evaluate whether there is a difference in the pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection or short-term intravenous infusion. In addition, we also investigated the influence of the erectile response on prostaglandin E1 kinetics after intracavernous injection.

We also recommend Trading Suppliers and Manufacturers of 13,14-DIHYDROPROSTAGLANDIN E1 (cas 19313-28-1). Pls Click Website Link as below: cas 19313-28-1 suppliers

Prev:1-Methyl-4-ferrocenylmethyl-3,5-diphenylpyrazole: A versatile ligand for palladium(II) and platinum(II)
Next:13,14-dihydro-prostaglandin E1 decreases low-density lipoprotein influx into rabbit aorta)